Johnson Investment Counsel’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Johnson Investment Counsel’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13,480	Closed	-$199K	–	796
2024 Q1	$199K	Buy	+13,480	New	+$189K	﹤0.01%	729

Other funds holding MACK

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Johnson Investment Counsel's MACK Position: Q2 2024 in Review

Johnson Investment Counsel sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 13,480 shares — an estimated $199K sold.

Johnson Investment Counsel first reported a position in MACK in Q1 2024 and held it in 1 quarter. The position peaked at $199K in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

Johnson Investment Counsel reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
Johnson Investment Counsel sold 13,480 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $199K.
Johnson Investment Counsel first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2024 and held it in 1 quarter.
Johnson Investment Counsel's Merrimack Pharmaceuticals, Inc. position peaked at $199K in Q1 2024.
12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Johnson Investment Counsel's 13F filing for Q2 2024, filed 8 Aug 2024.